Analyst Price Targets — PLYX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 10:30 am | — | Raymond James | $6.00 | $2.23 | TheFly | Polaryx initiated with a Strong Buy at Raymond James |
| July 9, 2026 10:13 am | Raghuram Selvaraju | H.C. Wainwright | $7.00 | $2.55 | TheFly | Polaryx initiated with a Buy at H.C. Wainwright |
Latest News for PLYX
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PLYX.
Senate Trading
No Senate trades found for PLYX.
U.S. House Trading
No House trades found for PLYX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.